Version 1
: Received: 22 December 2021 / Approved: 6 January 2022 / Online: 6 January 2022 (11:20:59 CET)
How to cite:
Damase, T.; Sukhovershin, R.; Zhang, M.; Kiss, D.; Cooke, J. Hospital-based RNA Therapeutics. Preprints2022, 2022010073 (doi: 10.20944/preprints202201.0073.v1).
Damase, T.; Sukhovershin, R.; Zhang, M.; Kiss, D.; Cooke, J. Hospital-based RNA Therapeutics. Preprints 2022, 2022010073 (doi: 10.20944/preprints202201.0073.v1).
Cite as:
Damase, T.; Sukhovershin, R.; Zhang, M.; Kiss, D.; Cooke, J. Hospital-based RNA Therapeutics. Preprints2022, 2022010073 (doi: 10.20944/preprints202201.0073.v1).
Damase, T.; Sukhovershin, R.; Zhang, M.; Kiss, D.; Cooke, J. Hospital-based RNA Therapeutics. Preprints 2022, 2022010073 (doi: 10.20944/preprints202201.0073.v1).
Abstract
Hospital-based programs democratize mRNA therapeutics by facilitating the processes to translate a novel RNA idea from the bench to the clinic. Because mRNA is essentially biological software, therapeutic RNA constructs can be rapidly developed. The generation of small batches of clinical grade mRNA to support IND applications and first-in-man clinical trials, as well as personalized mRNA therapeutics delivered at the point-of-care, is feasible at a modest scale of cGMP manufacturing. Advances in mRNA manufacturing science and innovations in mRNA biology, are increasing the scope of mRNA clinical applications.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.